CN114667130A - Hybrid inorganic-organic complex and use thereof for maintaining the microbial balance of skin and/or cosmetic and/or dermopharmaceutical compositions - Google Patents
Hybrid inorganic-organic complex and use thereof for maintaining the microbial balance of skin and/or cosmetic and/or dermopharmaceutical compositions Download PDFInfo
- Publication number
- CN114667130A CN114667130A CN202080053365.4A CN202080053365A CN114667130A CN 114667130 A CN114667130 A CN 114667130A CN 202080053365 A CN202080053365 A CN 202080053365A CN 114667130 A CN114667130 A CN 114667130A
- Authority
- CN
- China
- Prior art keywords
- cosmetic
- advantageously
- skin
- composition
- hybrid compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 79
- 239000002537 cosmetic Substances 0.000 title claims description 46
- 230000000813 microbial effect Effects 0.000 title description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000000084 colloidal system Substances 0.000 claims abstract description 32
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 27
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 26
- 239000002243 precursor Substances 0.000 claims abstract description 18
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims abstract description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims abstract description 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000004472 Lysine Substances 0.000 claims description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 13
- 230000035755 proliferation Effects 0.000 claims description 13
- 125000006850 spacer group Chemical group 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 108050004290 Cecropin Proteins 0.000 claims description 6
- 108010036176 Melitten Proteins 0.000 claims description 6
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 claims description 6
- 102000000541 Defensins Human genes 0.000 claims description 5
- 108010002069 Defensins Proteins 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 230000000249 desinfective effect Effects 0.000 claims description 4
- ISVYWKMWPYDXJS-IYCJPGOXSA-N diptericin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(C)C)C(C)C)[C@@H](C)O)C1=CN=CN1 ISVYWKMWPYDXJS-IYCJPGOXSA-N 0.000 claims description 4
- 125000000524 functional group Chemical group 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 101710086289 Attacin Proteins 0.000 claims description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 108060001132 cathelicidin Proteins 0.000 claims description 2
- 102000014509 cathelicidin Human genes 0.000 claims description 2
- ICZZXLGKHXWNSU-ULVOZOJHSA-N drosocin Chemical compound NC(=N)NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@H](C(C)CC)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(C(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]2N(CCC2)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]2N(CCC2)C(=O)[C@H](CO)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H]2N(CCC2)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]2N(CCC2)C(=O)[C@H](CCCCN)NC(=O)CN)C(C)O[C@@H]2[C@@H]([C@@H](O[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)CCC1 ICZZXLGKHXWNSU-ULVOZOJHSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 abstract description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 24
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 23
- 239000003755 preservative agent Substances 0.000 description 23
- 239000000284 extract Substances 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 244000005700 microbiome Species 0.000 description 17
- 239000000047 product Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 230000002335 preservative effect Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000011109 contamination Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229960003500 triclosan Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 244000118350 Andrographis paniculata Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 240000008067 Cucumis sativus Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 241000206754 Palmaria palmata Species 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229960002798 cetrimide Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- 231100000582 ATP assay Toxicity 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 2
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 235000016622 Filipendula ulmaria Nutrition 0.000 description 2
- 244000061544 Filipendula vulgaris Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 241001278898 Glycyrrhiza inflata Species 0.000 description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 2
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 description 2
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 2
- -1 LL-37) Chemical compound 0.000 description 2
- 241001466453 Laminaria Species 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- YOAHKNVSNCMZGQ-XPWFQUROSA-N P(1),P(4)-bis(5'-adenosyl) tetraphosphate Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 YOAHKNVSNCMZGQ-XPWFQUROSA-N 0.000 description 2
- 101800001442 Peptide pr Proteins 0.000 description 2
- 244000021273 Peumus boldus Species 0.000 description 2
- 244000037433 Pongamia pinnata Species 0.000 description 2
- 235000004599 Pongamia pinnata Nutrition 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 244000294617 Zanthoxylum alatum Species 0.000 description 2
- 235000004417 Zanthoxylum alatum Nutrition 0.000 description 2
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229940067599 ascorbyl glucoside Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- YSRSBDQINUMTIF-UHFFFAOYSA-N decane-1,2-diol Chemical compound CCCCCCCCC(O)CO YSRSBDQINUMTIF-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229940073499 decyl glucoside Drugs 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- OLGWXCQXRSSQPO-UHFFFAOYSA-N diguanosine tetraphosphate Natural products C1=NC(C(N=C(N)N2)=O)=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OCC(C(O)C1O)OC1N1C=NC2=C1NC(N)=NC2=O OLGWXCQXRSSQPO-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229940110977 polyglycerin-4 Drugs 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- 229940031723 1,2-octanediol Drugs 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 108091023231 Ap4A Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 244000139693 Arctostaphylos uva ursi Species 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100037437 Beta-defensin 1 Human genes 0.000 description 1
- 102100026887 Beta-defensin 103 Human genes 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- OWNRRUFOJXFKCU-UHFFFAOYSA-N Bromadiolone Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=CC=C1 OWNRRUFOJXFKCU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 description 1
- 101100459440 Caenorhabditis elegans nac-3 gene Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017543 Fungal skin infection Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 1
- 241000256023 Hyalophora cecropia Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000295519 Laminaria ochroleuca Species 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 101000883593 Nicotiana alata Flower-specific defensin Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- OLGWXCQXRSSQPO-MHARETSRSA-N P(1),P(4)-bis(5'-guanosyl) tetraphosphate Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=C(NC2=O)N)=C2N=C1 OLGWXCQXRSSQPO-MHARETSRSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 235000015933 Peumus boldus Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000015177 Saccharina japonica Species 0.000 description 1
- 241000983746 Saccharina latissima Species 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 229910008051 Si-OH Inorganic materials 0.000 description 1
- 229910006358 Si—OH Inorganic materials 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 206010065173 Viral skin infection Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000001535 azelaic acid derivatives Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960002788 cetrimonium chloride Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 229940080421 coco glucoside Drugs 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000046975 human DEFB1 Human genes 0.000 description 1
- 102000055779 human DEFB103A Human genes 0.000 description 1
- 102000049262 human DEFB4A Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- AIPVRBGBHQDAPX-UHFFFAOYSA-N hydroxy(methyl)silane Chemical compound C[SiH2]O AIPVRBGBHQDAPX-UHFFFAOYSA-N 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940093424 polyaminopropyl biguanide Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000009221 stress response pathway Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- SZEMGTQCPRNXEG-UHFFFAOYSA-M trimethyl(octadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C SZEMGTQCPRNXEG-UHFFFAOYSA-M 0.000 description 1
- GLFDLEXFOHUASB-UHFFFAOYSA-N trimethyl(tetradecyl)azanium Chemical compound CCCCCCCCCCCCCC[N+](C)(C)C GLFDLEXFOHUASB-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/612—By organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/614—By macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
A hybrid inorganic-organic composite is disclosed comprising a silica colloid covalently grafted with at least one antimicrobial peptide or antimicrobial precursor thereof.
Description
Technical Field
The present invention relates to a hybrid compound and its use for maintaining the microbial balance of skin and/or cosmetic or dermopharmaceutical compositions by reducing or inhibiting the activity of bacterial proliferation.
Background
The skin consists of several layers: the epidermis is the outermost layer, and the dermis and subcutaneous tissue constitute the deepest layer. The organ is the interface between the organism and the external environment. In particular, the epidermis is protective against physical (uv radiation, temperature, etc.), chemical (solvents, allergens, etc.) and even biological (pathogens) attacks. The term applied here is the epidermal barrier.
To combat pathogen attack, the epidermis has a primary immune defense mechanism. Thus, keratinocytes and langerhans cells recognize pathogenic microorganisms and become active to eliminate them by phenomena such as phagocytosis and presentation of microbial antigens to lymphocytes or by production of antimicrobial peptides.
This immune component is complemented by a second structural defense mechanism: desquamation processes, which ensure the elimination of superficial keratinocytes and resident microorganisms.
In the rest of the text, the term "microorganism" refers to living organisms that are not visible to the naked eye, corresponding to various life forms, including bacteria, fungi and even archaea.
The ecosystem consisting of saprophytic flora also provides the barrier function of the skin.
The saprophytic bacteria flora is natural and permanent on the skin surface. The number of bacteria on the skin surface is estimated at 10 per square centimeter of skin2To 105Between individual bacteria. The most representative species are staphylococci (in particular staphylococcus epidermidis), coagulase-negative and related (Micrococcus) and aerobic (corynebacteria), Brevibacterium (Brevibacterium) or anaerobic (Propionibacterium acnes)rium acnes)). These bacteria build up in the outermost layer of the epidermis, called the stratum corneum, which adheres to keratinocytes, forming a protective biofilm.
This saprophytic flora therefore acts as a barrier, since it occupies the adhesion sites of other microorganisms, which may be pathogenic, thus limiting their proliferation.
However, in the case of skin deterioration, such as in the case of pathological (atopic dermatitis, acne or psoriasis) or severe or repeated skin attacks, the deterioration of the skin barrier promotes the appearance of bacterial, viral and/or fungal skin infections.
Meanwhile, the skin may be a place where microorganisms are propagated by contacting daily supplies (especially, cosmetics).
Conventional cosmetic compositions are susceptible to contamination by various microorganisms both during their manufacture and during their use by consumers.
Therefore, the cosmetic industry places great importance on maintaining the microbiological integrity of its products, both for the safety needs of the consumer and for maintaining the good functionality and good physicochemical aspects of its products.
Due to their use and storage techniques, cosmetics are subject to temperature changes, resulting in a moisture evaporation-condensation cycle, which can alter the concentration of ingredients in the formulation. These products are also subject to humidity variations during their distribution, storage and/or use. During their use, the products are contaminated by contact with the external environment or with the skin. This risk is particularly evident with canned products, which have a larger exposed surface and are therefore more accessible to airborne pathogenic microorganisms. Without a suitable preservative system, cosmetics are substrates for the growth of various microorganisms such as Enterobacter (Enterobacter spp.) (e.cloacae) or Enterobacter agglomerans), Pseudomonas spp (Pseudomonas putida), Pseudomonas aeruginosa (p.aeruginosa) or Pseudomonas fluorescens), Bacillus spp (Bacillus spp.), and Staphylococcus spp (Staphylococcus aureus (s.aureus) or Staphylococcus saprophyticus (s.saprophyticus).
Among the many parameters that affect the storage of cosmetics, water activity plays an important role. In order to grow in cosmetics, microorganisms must be present in a certain amount of free water.
For the purposes of the present invention, the term "free water" means water molecules that are not complexed with other molecules used in the formulation of the composition. This amount of free water is called the "water activity" and is denoted aw。
A for microbial growthwThe minimum of (c) depends on their kind. However, a reduction in water activity tends to slow the growth of these pathogens.
For the remainder of the present disclosure, the terms "compound," "component," and "ingredient" are used interchangeably.
In order to reduce the amount of water, especially free water, in conventional cosmetic formulations, the current solution is to add specific components, such as humectants, which can reduce the amount of free water by forming hydrogen bonds between their hydrophilic functional groups and free water molecules.
Agents for altering the rheology of cosmetic formulations may also be used. These are, for example, gums (guar, xanthan, etc.) which can form a three-dimensional network, thereby reducing the mobility of free water molecules. However, gums, in turn, are often the primary source of bacterial and fungal contamination of products into which they are incorporated.
Each microorganism has an optimal growth pH, typically between 5 and 8. Thus, another solution used in conventional compositions is to change the pH of the formulation to less than 5. Thus, the microorganisms are under stress conditions that are not conducive to any growth. However, the addition of acidic compounds to cosmetic compositions is aggressive to the skin and can lead to skin irritation.
An alternative to the above preservative solutions is to add a preservative to the formulation. They may be synthetic preservatives, essential oils or even vegetable oils.
For the purposes of the present invention, the term "preservative" means a substance capable of inhibiting the growth of microorganisms in a cosmetic product. In Europe, all regulatory mandated preservatives and their use limit concentrations are included in the list (Annex V of the European Cosmetic Products Directive). However, some compounds not included in this list and not considered as authorized preservatives may contribute to the preservation of cosmetics.
The european directives mandate that preservatives are all synthetic sources with varying physicochemical properties, activities and modes of action. These differences allow the choice of preservative to be adjusted according to the product to be formulated. Preservatives are selected based on various criteria such as spectrum of activity, efficacy at low concentrations, solubility in water, compatibility with other ingredients or safety and ease of use.
However, the use of these preservatives presents a problem because they may be a source of skin irritation and/or sensitization, endocrine disorders, allergies, or even carcinogenic, as some preservatives are suspected of causing cancer.
For example, parabens are one of the approved synthetic preservatives widely used in the cosmetic industry.
Parabens are antimicrobial and antifungal agents, used primarily in cosmetic compositions, but also in food or pharmaceutical products. Their mode of action appears to be through denaturation of microbial and fungal membranes, which is said to result in protein changes. The range of action of parabens includes gram-positive bacteria, such as bacteria of the genus Staphylococcus (Staphylococcus), and some gram-negative bacteria, such as pseudomonas aeruginosa (p. Parabens are also active against yeasts and molds. However, they are very weak against bacterial spores and have no activity against viruses or mycobacteria. That is why they are most often used in combination with other types of preservatives.
However, parabens are suspected to disturb the endocrine system by mimicking the properties of certain hormones and lead to reproductive problems or cancer. In addition, parabens are suspected to be predictive of childhood obesity, or to have allergic and irritant effects.
Other ingredients are also used in conventional cosmetic formulations due to their natural antimicrobial properties. These are natural extracts from plant materials, having antifungal and/or antibacterial properties.
For example, essential oils are used for their antimicrobial activity. In particular, thyme, savory or oregano essential oils contain thymol and carvacrol, or clove essential oil contains eugenol, which are compounds known to be effective against the proliferation of pathogenic microorganisms.
Despite the antimicrobial properties of essential oils, the use of essential oils in cosmetics remains problematic due to their pronounced odor, the presence of allergens, and contraindications for children or pregnant women.
Also, certain cosmetic formulations, soaps and even toothpastes contain antibiotics (e.g. triclosan) as antimicrobial agents. Triclosan is known to increase the risk of allergies, loss of muscle strength, compromised immune systems, and even liver cancer risk factors. In addition, scientists have found that triclosan is often present in consumer products in too small an amount to exert any substantial antimicrobial effect. On the other hand, bacteria exposed to such antibiotics become stronger and more resistant to the antibiotics.
In particular, bacteria such as e.coli (e.coli) increase the activity of their stress response pathways and become more resistant in the presence of triclosan. This is a phenomenon of antibiotic resistance. Then four times more triclosan and eight times more quinolone (antibiotics used against these bacteria) are needed to prevent their proliferation.
Therefore, there is a clear need to develop a new generation of compounds that ensure the inhibition or reduction of the proliferation of microorganisms in cosmetic compositions and/or on the skin and that do not have the drawbacks of the prior art ingredients.
Disclosure of Invention
Applicants have developed a hybrid inorganic-organic composite that can reduce, reduce or even inhibit microbial proliferation in cosmetic compositions and/or on the skin.
The present invention solves the above-mentioned problems of the prior art.
According to a first aspect, the present invention relates to a hybrid inorganic-organic composite comprising a silica colloid covalently grafted by a spacer arm with at least one peptide or precursor thereof.
Silicon dioxide with SiO2Is naturally occurring and is part of many inorganic compositions. It exists in its free state in various crystalline or amorphous forms and in a bound state in silicates.
According to a particular embodiment, the silicate used for the production of the silica colloid according to the invention corresponds to tetraethylorthosilicate.
In practice, the silica according to the invention can be used in purified or isolated form, with a purity at least equal to 60%, preferably at least equal to 70%, advantageously at least equal to 80%, even more advantageously at least equal to 90%, or even 95%, preferably at least 98%, advantageously 99% or even 100%.
Silica colloids are surface-modifiable, biocompatible and exhibit good dispersibility and stability in hydrophilic media.
The size, shape, porosity and crystallinity of the silica colloid may vary depending on the intended application (e.g. in the biomedical, pharmaceutical or cosmetic field). Furthermore, the variety of possible surface modifications allows control of different parameters, such as dispersion, circulation and targeting ability of the silica colloid.
According to the invention, colloid refers to particles in crystalline or amorphous form. In a liquid medium, for example an aqueous medium, the colloid forms a colloidal suspension.
The concept of colloidal grafting is part of the common general knowledge of the skilled person. Grafting corresponds to the formation of covalent bonds, for example, between a peptide or precursor thereof and the surface of the silica colloid.
According to the invention, the covalent grafting is carried out via spacer arms or "linkers".
According to a particular embodiment, the spacer arm may comprise a functional group of the ether, ester, phosphate or amide type, advantageously an ether.
Advantageously, the spacer arm is a linear ether comprising from 3 to 10 carbons (preferably from 4 to 6 carbons).
According to the invention, the spacer has no specific affinity to the microbial plasma membrane (preferably the bacterial plasma membrane).
It goes without saying that grafting is not limited to grafting individual compounds. It is a molecule or molecules of at least one compound grafted onto each silica particle.
The colloids may be synthesized according to conventional techniques, for example by
A method.
Generally, the average size of the colloid is on the order of several nanometers to several tens of nanometers.
The size of the colloids according to the invention is therefore advantageously between 0.1nm and 1000nm, more advantageously between 0.3nm and 100nm, even more advantageously of the order of 5nm, advantageously measured by DLS.
DLS (dynamic light scattering) is a technique conventionally used to measure the size of colloids in fluids.
According to a particular embodiment, the hybrid compound according to the invention comprises a silica colloid to which at least one peptide having antimicrobial activity or a precursor thereof is covalently grafted.
The grafting of the peptide or antimicrobial precursor thereof on the silica colloid is carried out via a spacer arm or "linker".
According to a particular embodiment, the grafting of the silica colloid with at least one peptide or its precursor (preferably a peptide or its antimicrobial precursor) is carried out by chemical reaction with an alkoxysilane or halosilane (advantageously an alkoxysilane), for example by creating a covalent bond by nucleophilic substitution between the terminal amine of the peptide or its precursor and the reactive end of the spacer arm.
Preferably, the grafting of the silica colloid with at least one precursor or peptide thereof is carried out with (3-glycidoxypropyl) trimethoxysilane.
This is a conventional reaction known to those skilled in the art for grafting silica colloids with spacer arms. This reaction takes place between the surface of the silica colloid comprising Si-OH functional groups and the spacer, which is advantageously an alkoxysilane or halosilane, preferably an alkoxysilane, even more advantageously (3-glycidoxypropyl) trimethoxysilane.
For the purposes of the present invention, the term "peptide" optionally denotes a polymer of amino acids.
For the purposes of the present invention, the term "peptide precursor" denotes an amino acid, i.e. an amino acid monomer, which can be converted into a peptide by natural, biotechnological or artificial peptide synthesis. Synthetic peptides may be modified (e.g., glycosylated, acylated, and/or acetylated), which may modulate their activity and/or properties.
For the purposes of the present invention, the term "peptide or antimicrobial precursor thereof" denotes a peptide or precursor thereof having properties such that it is capable of inhibiting, slowing or reducing the growth of a microorganism (e.g. bacteria, fungi, viruses, yeasts and/or protozoa).
According to a particular embodiment, the peptide or precursor thereof according to the invention is selected from the group comprising: CM15(SEQ ID NO:1), lysine, drosophila rhzomorph (drosocin), cecropin (attacin), diptericin (diptericin), melittin (melittin), cathelicidin (e.g., LL-37), defensin (defensin) (e.g., human beta-defensin-1, human beta-defensin-2 or human beta-defensin-3 (or hBD-1, h-BD-2 or hBD-3)) or a plant defensin from Nicotiana sativa (or NaD1 or NaD2) and mixtures thereof.
According to a particular embodiment, the hybrid compound according to the invention comprises a silica colloid covalently grafted with at least one peptide or precursor thereof, the colloid/peptide or precursor mass ratio of the compound being between 99.9:0.1 and 90:10, advantageously between 99:1 and 90:10, preferably between 93:7 and 94: 6.
According to a particular embodiment, the invention relates to a hybrid compound Comprising Silica Colloids (CSCs) grafted with at least one CM15, the colloid/CM 15 mass ratio of the compound being between 99.9:0.1 and 90:10, advantageously between 99:1 and 90:10, preferably between 93:7 and 94: 6.
CM15 is a 15 amino acid multifunctional hybrid cationic peptide (or MCP) (SEQ ID NO: 1). Specifically, CM15 is a hybrid peptide consisting of 2 peptides, cecropin (cecropin) and melittin (melittin) from the hemolymph of the butterfly-carved crinopsis kefir (Hyalophora cecropia).
According to the present invention, the hybrid compounds comprising CSCs have antimicrobial properties with an advantageous efficacy/minimum inhibitory concentration ratio, which is present in particular in the negative charge carried by the silica colloid. These negative charges are the origin of the phenomenon of element repulsion of microbial membranes, particularly negatively charged bacterial membranes. This phenomenon allows the hybrid complex to cross the membrane of the microorganism (e.g., bacteria) and enter the plasma membrane, particularly bacteria, which leads to degradation of the microorganism.
According to the invention, CSC hybrid complexes allow CM15 to maintain its original conformation in solution and thus increase or improve its efficiency.
According to another particular embodiment, the hybrid compound according to the invention comprises a silica Colloid (CSL) covalently grafted with at least one lysine as peptide precursor.
According to a particular embodiment, the invention relates to a hybrid compound comprising CSL, the colloid/lysine mass ratio of which is between 99:1 and 90:10, advantageously between 95:5 and 94:6, preferably between 93:7 and 94: 6.
Lysine is a positively charged amino acid contained in the composition of proteins. Such amino acids are important building blocks that make up many antimicrobial peptides. For example, cecropin (cecropin) is rich in lysine.
Such amino acids, which are also part of the composition of lysine homopolymers, are called polylysines, which differ in length (25 to 30 amino acids) and possibly in stereochemistry and bond position from each other. Studies have shown that polylysine has antimicrobial properties.
The grafting of lysine onto the silica colloid according to the invention makes it possible to immobilize and electronically stabilize the lysine, which helps to promote the penetration of CSL into the microbial, in particular bacterial, membrane in order to eliminate said microorganisms.
According to another aspect, the present invention relates to a cosmetic or dermopharmaceutical composition comprising the hybrid compound as described above.
According to a particular embodiment, the present invention relates to a cosmetic or dermopharmaceutical composition comprising CSCs and/or CSLs.
Advantageously, the hybrid compound according to the invention (in particular the CSC and/or CSL) represents from 0.001% to 2%, preferably from 0.01% to 1%, alternatively from 0.1% to 1% of the total weight of the composition.
The composition comprising the hybrid compound according to the invention, advantageously the CSC and/or CSL, may be provided in all galenic forms commonly used in cosmetics and dermatology, for example but not limited to in the form of an optionally gelled aqueous solution, a dispersion of the emulsion (deposition) type, an O/W or inverse W/O emulsion (emulsion), a more or less fluid, or a multiple emulsion (e.g. a triple emulsion (W/O/E or O/W/O)), or in the form of a vesicular dispersion of ionic (liposome) and/or non-ionic type, which is a two-phase composition free of emulsifier and gelling agent, the immiscible phases of which separate during storage, frothing, spraying or misting.
According to a particular embodiment, the cosmetic or dermopharmaceutical composition comprising the hybrid compound according to the invention (advantageously the CSC and/or CSL) is in the form of a water-based solution, dispersion, emulsion or emulsion.
According to a particular embodiment, the cosmetic or dermopharmaceutical composition comprising the hybrid compound according to the invention (advantageously the CSC and/or CSL) is an aqueous solution further comprising at least one surfactant.
In a preferred embodiment, the surfactant is a nonionic surfactant selected from the group comprising Alkyl Polyglucosides (APGs), polyglyceryl fatty alcohols, ethoxylated derivatives and polysorbates.
According to a particular embodiment, the alkylpolyglucoside comprises an alkyl group containing from 6 to 30 carbon atoms, preferably from 8 to 16 carbon atoms, and comprises a hydrophilic group (glucoside) preferably containing 1,2 or 3 saccharide units.
Examples of alkylpolyglucosides according to the invention may be, for example, compounds corresponding to the following INCI names:
sucrose stearate, sold under the name Sisterna SP70-C by SISTERNA;
decyl glucoside (or alkyl-C9/C11-polyglucoside (1.4)), by KAO CHEMICALS under the name MYDOLTM10. By BASF under the name PLANTARENTM2000UP, or by SEPPIC under the name ORAMIX NSTM10, selling;
octyl/decyl glucoside, by BASF under the name PLANTACARETM810UP for sale;
lauryl glucoside, by BASF under the name PLANTARENTM1200N and PLANTACARETM1200, sale; and
coco glucoside, by BASF under the name PLANTACARETM818/UP for sale.
As polyglycerin fatty alcohols according to the invention, mention may be made, by way of example, of Tegosoft, a raw material sold by EVONIK and corresponding to the INCI names polyglycerin-4 decanoate and polyglycerin-6 octanoate/polyglycerin-4 decanoate, respectivelyTM PC 41、TegoSolveTM 90MB。
Advantageously, the composition comprising the hybrid compound according to the invention (advantageously the CSC and/or CSL) comprises from 0.5% to 20%, preferably from 1% to 10% or alternatively from 1% to 5% by total weight of the surfactant composition.
According to a particular embodiment, the composition comprising the hybrid compound according to the invention (advantageously CSC and/or CSL) is free of ethoxylated derivatives, preferably free of surfactants derived from polyethylene glycol (PEG).
According to another embodiment, the composition according to the invention comprises an inorganic and organic hybrid complex comprising a silica colloid covalently grafted by a spacer arm with at least one peptide or its precursor (advantageously CSC and/or CSL) and at least one preservative.
Any preservative, authorized or not by regulations applicable to Cosmetic or dermatological compositions (Annex V of the European Cosmetic Products Directive), may be used to formulate compositions comprising the hybrid complex according to the invention (advantageously the CSC and/or CSL).
According to a particular embodiment, the preservative according to the invention is an alkanediol.
Preferably, the preservative according to the present invention is a 1, 2-alkanediol or a 1, 3-alkanediol.
According to a particular embodiment, the alkanediol is selected from the group comprising compounds corresponding to the following INCI names: propylene glycol, 1, 3-propanediol, 2-methyl-1, 3-propanediol, 1, 2-pentanediol, 1, 2-hexanediol, octanediol, 1, 2-decanediol, hexanediol, and mixtures thereof.
These preservatives are available from a variety of cosmetic raw material suppliers.
By way of example, we can cite:
-EVO-100TMpropylene glycol, sold by ARCHER DANIELS MIDLAND COMPANY and corresponding to the INCI name;
-ZEMEATMfrom DUPONT-TATE&LYLE biproducts, marketed and corresponding to INCI name 1, 2-propanediol;
-DUB DIOLTM2-methyl-1, 3-propanediol sold by STEARINERIE DUBOIS and corresponding to the INCI name;
-Hydrolite-5TM、Hydrolite-6TM、Hydrolite-8TMand SymClariol 344028TMMarketed by sym rise and corresponding to INCI names 1, 2-pentanediol, 1, 2-hexanediol, octanediol, and 1, 2-decanediol, respectively;
-HexasolTMhexanediol, sold by ARKEMA and corresponding to the INCI name.
According to another embodiment, the preservative is a quaternary ammonium salt selected from the group consisting of docosanyltrimethylammonium chloride, cetrimonium bromide, myristyltrimethylammonium bromide, cetrimonium chloride, lauryltrimethylammonium bromide, lauryltrimethylammonium chloride, stearyltrimethylammonium bromide, stearyltrimethylammonium chloride, benzethonium chloride, benzalkonium chloride, and mixtures thereof.
According to a particular embodiment, the preservative corresponding to the quaternary ammonium salt is cetrimide and/or myristyl trimethyl ammonium bromide, advantageously cetrimide.
For example, cetrimide is available from MERCK under the trade name RONACARETMCETRIMONIUM BROMIDE, and myristyltrimethylammonium BROMIDEFrom COSPHATECH LLC under the trade name iBact CetrimideTMAnd (5) selling.
Further preservatives suitable for use in the composition comprising the hybrid compound according to the invention (advantageously CSC and/or CSL) are, for example:
potassium sorbate (INCI), sodium benzoate (INCI) and benzyl alcohol (INCI), respectively under the name Paratexin from AZELIS UKTM KS、ParatexinTMSBG and ParatexinTMSelling BA;
p-anisic acid (INCI) and levulinic acid (INCI), respectively under the name Cosphaederm from Cosphaec GMBHTMAnd CophadermTMLA-T sales;
dehydroacetic acid (INCI) and polyaminopropylbiguanide (INCI), respectively Geogard by the name LONZATM111A andTMselling CQ;
phenoxyethanol (INCI) under the name Phenoxetol by CLARIANT INTERNATIONAL LTD CosmosilTMAnd (5) selling.
According to a particular embodiment, the composition comprising the hybrid compound according to the invention (advantageously the CSC and/or CSL) comprises from 0.001% to 5%, advantageously from 0.01% to 2%, preferably from 0.1% to 1% of preservative by total weight of the composition.
The composition comprising the hybrid compound according to the invention (advantageously CSC and/or CSL) may also comprise at least one dermocosmetic active ingredient, such as:
-lysine azelaic acid salt or derivatives thereof or azelaic acid salt;
andrographolide, in particular an Andrographis paniculata extract corresponding to the INCI name Andrographis paniculata (Andrographis paniculata) leaf extract;
natural ascorbic acid (vitamin C) or its derivatives, in particular derivatives corresponding to INCI ascorbyl glucoside, ascorbyl ethyl ether, ascorbyl methylsilanol pectate, sodium ascorbyl phosphate and ascorbyl tetraisopalmitate, advantageously ascorbyl glucoside;
arbutin or a plant extract containing it, in particular an extract of arbutin corresponding to the INCI name extract of the leaves of arbutin (Arctostaphylos uva-ursi);
glabridin or plant extracts containing it, in particular licorice extracts corresponding to the INCI name Glycyrrhiza glabra (Glycyrrhiza glabra) root extract, Glycyrrhiza inflata (Glycyrrhiza inflata) root extract, Glycyrrhiza uralensis (Glycyrrhiza uralensis) root extract;
-a biomimetic peptide corresponding to the INCI name hexapeptide-2 and/or nonapeptide-1;
-an aqueous extract of the alga known as Palmaria palmata (Palmaria palmata), in particular an extract corresponding to the INCI name Palmaria palmata extract;
-4-n-butylresorcinol;
-vitamin PP (also known as niacinamide) and its derivatives;
-at least one polyol, in particular selected from xylitol, rhamnose, mannitol and mixtures thereof;
-fructooligosaccharides;
-extracts of the algae Laminaria cuneata (Laminaria ochroleuca), Laminaria japonica (Blidinia minima) and/or Laminaria saccharina (Laminaria saccharana);
-an extract of the plant Zanthoxylum armatum (Zanthoxylum armatum);
-panthenol;
-vitamin E or one of its hydrophilic or lipophilic derivatives, or one of their salts, advantageously tocotrienols or tocopherols;
-salicylic acid or one of its derivatives;
-juniper (cade wood) extract;
-an extract from Boldo tree (Boldo);
-an extract from Meadowsweet (Meadowsweet);
-an agent limiting immunosuppression, advantageously vitamin PP;
-a protectant of the p53 protein, advantageously epigallocatechin gallate (EGCG);
-a karanja oil extract from karanja (pongama gladra);
-ATP (adenosine-5-triphosphate), Gp4G (diguanosine tetraphosphate) or Ap4A (diadenosine tetraphosphate); -peptide extracts of soybean and/or wheat and mixtures thereof;
-an amino acid or amino acid derivative selected from the group consisting of ectoin, creatine, ergothioneine, carnosine, tyrosine, decarboxylated carnosine, glutamine and salts thereof;
-an aqueous Cucumber extract corresponding to the INCI name Cucumber (Cucumis sativus) (cucumer) fruit extract;
-or mixtures thereof.
Advantageously, the composition comprising the hybrid compound according to the invention (advantageously CSC and/or CSL) further comprises from 0.001% to 10%, advantageously from 0.01% to 5%, preferably from 0.1% to 1%, by total weight of the composition, of a skin cosmetic active ingredient.
The composition comprising the hybrid compound according to the invention (advantageously CSC and/or CSL) may also comprise adjuvants conventional in the field considered, for example hydrophilic or lipophilic thickeners or gelling agents, hydrophilic or lipophilic additives, antioxidants, perfumes, fillers, pigments, UV filters, odour absorbers, dyes, humectants, vitamins, essential fatty acids, liposoluble polymers (in particular hydrocarbons), opacifiers, stabilizers, chelating agents, conditioning agents, propellants, fatty substances, organic solvents, silicones, thickeners, emollients, anionic, cationic, nonionic or amphoteric polymers, antifoams, hair conditioning agents (for example proteins, vitamins, dyes), pearlescent agents, sunscreens, especially hydrophilic sunscreens, electrolytes, stabilizers, buffers (for example citric acid/sodium citrate buffer).
According to another aspect, the invention relates to the use of the hybrid compound as described above as an agent for disinfecting skin.
According to the invention, the hybrid compound as skin cleanser can:
-maintaining and rebalancing skin microbiota;
-reducing or inhibiting proliferation of pathogenic bacteria; and/or
-elimination of pathogenic bacteria.
According to another aspect, the invention relates to the use of the hybrid compound as described above as an agent for disinfecting cosmetic or dermopharmaceutical compositions.
According to the invention, the hybrid compound as a disinfectant of the composition may:
-protecting the composition from bacterial contamination;
-reducing or inhibiting the proliferation of pathogenic bacteria; and/or
-elimination of pathogenic bacteria.
In other words, the invention relates to the use of the hybrid compound as described above as an agent for disinfecting the skin and/or a cosmetic or dermopharmaceutical composition.
According to a particular embodiment, the hybrid compound is for use in reducing, reducing or inhibiting the proliferation of pathogenic bacteria on the skin and/or in a cosmetic or dermopharmaceutical composition.
Drawings
The invention and the advantages resulting therefrom will appear more clearly from the following figures and examples, which are given by way of illustration and are not limiting.
Fig. 1 shows the antimicrobial activity of the hybrid complexes corresponding to CSCs according to the present invention compared to the antimicrobial activity of CM15 alone.
FIG. 2 shows the comparison of the antimicrobial activity of the hybrid compound corresponding to CSL according to the invention with the antimicrobial activity of lysine alone.
Detailed Description
1/overview of CSL according to the invention
The compositions used for the synthesis of CSL according to the invention are shown in table 1.
[ Table 1]
Step 1: b was dissolved in A at 60 ℃ for 20 minutes.
Step 2: c was added to the solution obtained in step 1, and the mixture was heated to 60 ℃ and stirred for 20 hours.
Step 3: the suspension obtained in step 2 was cooled to room temperature and then filtered under vacuum through a 0.4 μm filter.
Step 4: d was added to the reaction mixture from step 3, and then the reaction was maintained at 40 ℃ for 16 hours.
Step 5: after a purification step by dialysis of the mixture according to step 4, silica Colloids (CSL) covalently grafted with lysine according to the invention were obtained, first dialyzed against 5g/L of E solution for 15 hours, with 3 changes of stripping solvent, and then against A for 15 hours, with 3 changes of stripping solvent. The dialysis membrane used had an exclusion limit of 3.5 kDa. The dust was removed by filtration through a 0.2 μm cellulose acetate filter.
2/overview of CSC according to the invention
The compositions used to synthesize the CSCs according to the invention are shown in table 2.
[ Table 2]
Step 1: b was dissolved in A at 60 ℃ for 20 minutes. The pH of the solution was about 10.3.
Step 2: c was added to the solution obtained in step 1, and the mixture was heated to 60 ℃ and stirred for 20 hours.
Step 3: the suspension obtained in step 2 was cooled to room temperature and then filtered under vacuum through a 0.4 μm filter.
The solution was then dialyzed against a 1kDa exclusion limit dialysis membrane, first against 5g/L of solution D for 15 hours, with 3 changes of stripping solvent, and then against A for 15 hours with 3 changes of stripping solvent.
The pH of the solution obtained after dialysis was between 8 and 9.5, which was then adjusted between 7.5 and 8 by adding the necessary amount of 0.1M HCl solution.
Step 4: for chemical grafting, E, then F were added to the solution obtained in step 3 in the dark and the reaction was maintained at 40 ℃ for 16 hours in the dark.
Step 5: silica Colloids (CSCs) covalently grafted with CM15 according to the invention were obtained after a purification step by dialysis of the mixture according to step 4 with a for 15 hours. The dialysis membrane used had an exclusion limit of 3.5 kDa. The dust was removed by filtration through a 0.2 μm cellulose acetate filter.
3/evaluation of antimicrobial Properties of CSC and CSL hybrid complexes according to the invention
The antimicrobial capacity of the hybrid CSC and CSL complex according to the invention is determined in vitro according to the ATP assay principle.
This technique involves measuring the amount of ATP present in a sample.
All living organisms contain ATP. ATP is quantified by a bioluminescent reaction using luciferase. This enzyme catalyzes the reaction between fluorescein (substrate), ATP (cofactor) and oxygen, which is responsible for the emission of photons.
In fact, every ATP molecule consumed in the reaction produces a photon. Thus, the light production in this reaction is directly proportional to the amount of biological energy (ATP) present in the sample.
The amount of ATP measured was converted into the number of microorganisms by considering the consensus that the bacteria (e.g.E.coli) contained 0.001pg ATP.
Assessment of the antimicrobial properties of CSC and CSL hybrid complexes is performed using an ATP assay kit comprising lysis buffer that can extract cellular ATP, resin that can capture substances that may interfere with the assay, ATP stabilization buffer (not extracted from live cells) that is pre-solubilized, standard solution of ATP, and luciferase.
The amount of ATP measured after treatment with lysis buffer and resin corresponds to the total amount of ATP contained in the sample.
The value obtained for dissolved ATP is subtracted from the value for total ATP to provide the cellular ATP concentration from which the concentration of viable biomass present in the assay sample can be inferred.
The analysis was performed in the presence of CM15 peptide alone, lysine alone or in a solution comprising CSCs or CSLs according to the invention.
a/sample preparation
1.5mL of each study sample was placed in a 5mL glass vial. All samples were then contaminated with either glucose solution (method 1) or skin contact (method 2).
Method 1-glucose contamination: 1g/L glucose aqueous solution is prepared and stored for 3 days at room temperature to promote the growth of microorganisms. This solution was then added to the sample to be tested at a concentration of 25% by weight of the sample.
Method 2-contamination by skin contact: 100 μ L of the test sample was collected and placed in contact with the palm of the individual's hand (3 inhalations and refluxes). The skin contains 10 per square centimeter2To 105And (4) bacteria. These bacteria belong to either resident (non-pathogenic) or transient (potentially pathogenic) bacteria. Unlike method 1, this technique of contamination ensures that the sample contains as many bacteria as possible in contact with the cosmetic or dermopharmaceutical preparation.
b/determination of the amount of ATP in the sample
Determination of the Total amount of ATP
mu.L of the sample was mixed with 40. mu.L of lysis buffer. After one minute incubation at room temperature, 50. mu.L of the mixture was placed in 200. mu.L of resin. After homogenizing the mixture, the supernatant was analyzed for luminescence by adding 10. mu.L of the mixture to 10. mu.L of luciferase in a 384-well plate.
Determination of the amount of dissolved ATP
mu.L of the sample was mixed with 300. mu.L of stabilization buffer. After homogenization and incubation for one minute at room temperature, the luminescence of the solution was analyzed by mixing a volume of 10 μ L of sample with 10 μ L of luciferase in 384-well plates.
The amount of ATP was initially quantified after contamination (T0). The samples were placed in a climate chamber at 40 ℃ and 75% relative humidity for 3 days. Then, ATP was newly quantified (T3 ═ T3 days after contamination).
The values obtained in cellular ATP were converted into microbial equivalents.
comparison of antimicrobial Activity of c/CSC with CM15 alone
CSC (concentration 1X 10) according to the invention-3、1×10-4Or 1X 10-5mg/mL) was compared to the antimicrobial activity of CM15 alone (i.e., in a free, ungrafted state) used at the same concentration.
The results are shown in FIG. 1.
The data indicate that no antimicrobial effect was seen with CM15 alone, regardless of the concentration of CM15 used.
In contrast, the concentrations used were 1X 10 respectively-3、1×10-4Or 1X 10-5The mg/mL CSC significantly inhibited bacterial proliferation by 75.5%, 70.6% and 87.7%.
Comparison of the antimicrobial Activity of d/CSL with lysine alone
The antimicrobial activity of CSL according to the invention (at concentrations of 0.5, 0.2 or 0.05mg/mL) was compared with the antimicrobial activity of lysine alone (i.e. in a free, ungrafted state) used at the same concentration.
The results are shown in FIG. 2.
The data show that at concentrations of 0.5mg/mL or 0.2mg/mL, CSL inhibits bacterial overgrowth as well as lysine alone.
In contrast, the use of CSL at a concentration of 0.05mg/mL significantly inhibited the proliferation of 70% of the bacteria, whereas lysine alone had no inhibitory effect on this proliferation.
4/example of composition-micellar Water, foamed hygiene products and milks comprising CSL or CSC according to the invention
Liquid for treating urinary tract infection
In the table below, the percentages indicated are given in terms of weight of product relative to the total weight of the composition.
The formulation of the composition comprising micellar water of CSL according to the invention is shown in table 3.
[ Table 3]
The formulation of the composition of micellar water comprising the CSCs according to the invention is shown in table 4.
[ Table 4]
The formulation of the composition corresponding to the foaming hygiene article (body wash) comprising the CSL according to the invention is shown in table 5.
[ Table 5]
The formulation of a cosmetic O/W emulsion comprising CSL according to the invention is shown in table 6.
[ Table 6]
| Water (W) | 61.801 |
| Decyl oleate | 13.496625 |
| Glycerol | 10.00 |
| Methyl propylene glycol | 5.00 |
| Behenyl alcohol | 4.50 |
| Hydrogenated castor oil | 2.00 |
| Sucrose laurate | 1.00 |
| Sucrose stearate | 1.00 |
| Dehydro xanthan gum | 0.50 |
| Citric acid sodium salt | 0.50 |
| Citric acid | 0.184 |
| Di-covalently grafted with lysine according to the inventionColloidal silica (example 1) | 0.015 |
| Tocopherol | 0.002194 |
| Hydrogenated palm oil glycerides citrate | 0.001181 |
Sequence listing
<110> Biaonikley Co
<120> hybrid inorganic-organic complexes and their use for maintaining the microbial balance of skin and/or cosmetic and/or dermopharmaceutical compositions
<130> B374-B-55515 PCT
<150> FR1908575
<151> 2019-07-26
<160> 1
<170> BiSSAP 1.3.6
<210> 1
<211> 15
<212> PRT
<213> Artificial sequence
<220>
<223> CM15
<400> 1
Lys Trp Lys Leu Phe Lys Lys Ile Gly Ala Val Leu Lys Val Leu
1 5 10 15
Claims (10)
1. An inorganic-organic hybrid compound comprising a silica colloid covalently grafted via a spacer arm to at least one antimicrobial peptide or antimicrobial precursor thereof.
2. Hybrid compound according to claim 1, characterized in that the spacer arm comprises a functional group of the ether, ester, phosphate or amide type, advantageously an ether, preferably a linear ether comprising 3 to 10 carbons, advantageously 4 to 6 carbons.
3. The hybrid compound according to any one of the preceding claims, characterized in that at least one peptide or its precursor is selected from the group comprising: CM15(SEQ ID NO:1), lysine, drosophila rhzomorph (drosocin), cecropin (attacin), diptericin (diptericin), melittin (melittin), defensin (defensin), cathelicidin and mixtures thereof.
4. The hybrid compound according to any one of claims 1 to 3, characterized in that the colloid/peptide or precursor mass ratio is from 99.9:0.1 to 90:10, advantageously from 93:7 to 94: 6.
5. A cosmetic or dermopharmaceutical composition comprising the hybrid complex of any one of claims 1 to 4.
6. Cosmetic or dermopharmaceutical composition, according to claim 5, characterized in that said hybrid compound represents from 0.001% to 2%, preferably from 0.01% to 1% of the total weight of the composition.
7. Cosmetic or dermopharmaceutical composition, according to claim 5 or 6, characterized in that it is in the form of a water-based solution, dispersion of an emulsion or emulsion.
8. Cosmetic or dermopharmaceutical composition, according to any of claims 5 to 7, characterized in that it is free of surfactants derived from polyethylene glycol.
9. Use of the hybrid compound according to any one of claims 1 to 4 or the cosmetic or dermopharmaceutical composition according to any one of claims 5 to 8 as an agent for disinfecting skin and/or a cosmetic or dermopharmaceutical composition.
10. Use according to claim 9, for reducing, reducing or inhibiting bacterial proliferation on the skin and/or in a cosmetic or dermopharmaceutical composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1908575A FR3099060B1 (en) | 2019-07-26 | 2019-07-26 | MINERAL AND ORGANIC HYBRID COMPLEX AND ITS USE FOR MAINTAINING THE MICROBIOLOGICAL BALANCE OF THE SKIN AND/OR OF A COSMETIC AND/OR DERMOPHARMACEUTICAL COMPOSITION |
| FRFR1908575 | 2019-07-26 | ||
| PCT/EP2020/070642 WO2021018682A1 (en) | 2019-07-26 | 2020-07-22 | Hybrid mineral-organic complex, and use thereof for maintaining the microbiological balance of the skin and/or of a cosmetic and/or dermopharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114667130A true CN114667130A (en) | 2022-06-24 |
Family
ID=68806993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080053365.4A Pending CN114667130A (en) | 2019-07-26 | 2020-07-22 | Hybrid inorganic-organic complex and use thereof for maintaining the microbial balance of skin and/or cosmetic and/or dermopharmaceutical compositions |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4003269A1 (en) |
| CN (1) | CN114667130A (en) |
| FR (1) | FR3099060B1 (en) |
| WO (1) | WO2021018682A1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4927749A (en) * | 1986-04-09 | 1990-05-22 | Jeanette Simpson | Reagent for cell separation |
| WO2002079408A2 (en) * | 2001-03-28 | 2002-10-10 | Helix Biomedix, Inc. | Short bioactive peptides and methods for their use |
| JP2005053852A (en) * | 2003-08-06 | 2005-03-03 | Kao Corp | Cocohesion inhibitor |
| US20090215096A1 (en) * | 2006-08-10 | 2009-08-27 | The Furukawa Electric Co., Ltd. | Collodial silica particle containing light-absorbing susbstance, nano light-absorbing material,absorption labeling nanobead kit, and method for detection or quantification of biological molecule using the colloidal silica particle containing light-absorbing substance |
| CN102391300A (en) * | 2011-08-30 | 2012-03-28 | 上海大学 | Organic/ inorganic composite lamellar compound containing glutathione (GSH) and preparation method thereof |
| FR2992318A1 (en) * | 2012-06-22 | 2013-12-27 | Centre Nat Rech Scient | PEPTIDE-SILICE HYBRID MATERIALS |
| CN106552600A (en) * | 2016-10-18 | 2017-04-05 | 武汉理工大学 | A kind of magnetic shell-core structure nanoparticle and preparation method and application |
-
2019
- 2019-07-26 FR FR1908575A patent/FR3099060B1/en active Active
-
2020
- 2020-07-22 WO PCT/EP2020/070642 patent/WO2021018682A1/en unknown
- 2020-07-22 CN CN202080053365.4A patent/CN114667130A/en active Pending
- 2020-07-22 EP EP20740649.7A patent/EP4003269A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4927749A (en) * | 1986-04-09 | 1990-05-22 | Jeanette Simpson | Reagent for cell separation |
| WO2002079408A2 (en) * | 2001-03-28 | 2002-10-10 | Helix Biomedix, Inc. | Short bioactive peptides and methods for their use |
| JP2005053852A (en) * | 2003-08-06 | 2005-03-03 | Kao Corp | Cocohesion inhibitor |
| US20090215096A1 (en) * | 2006-08-10 | 2009-08-27 | The Furukawa Electric Co., Ltd. | Collodial silica particle containing light-absorbing susbstance, nano light-absorbing material,absorption labeling nanobead kit, and method for detection or quantification of biological molecule using the colloidal silica particle containing light-absorbing substance |
| CN102391300A (en) * | 2011-08-30 | 2012-03-28 | 上海大学 | Organic/ inorganic composite lamellar compound containing glutathione (GSH) and preparation method thereof |
| FR2992318A1 (en) * | 2012-06-22 | 2013-12-27 | Centre Nat Rech Scient | PEPTIDE-SILICE HYBRID MATERIALS |
| CN106552600A (en) * | 2016-10-18 | 2017-04-05 | 武汉理工大学 | A kind of magnetic shell-core structure nanoparticle and preparation method and application |
Non-Patent Citations (4)
| Title |
|---|
| GUIJIAN GUAN等: ""Protein-building molecular recognition sites by layer-by-layer molecular imprinting on colloidal particles"", 《ANALYST》, vol. 134, pages 1880, XP055682413, DOI: 10.1039/b820962f * |
| HEEJUN CHOI等: ""Single-cell, real-time detection of oxidative stress induced in Escherichia coli by the antimicrobial peptide CM15"", 《PNAS》, vol. 112, no. 3, pages 303 - 310 * |
| VICTORIA N. SYRYAMINA等: ""Peptides on the Surface:Spin-Label EPR and PELDOR Study of Adsorption of the Antimicrobial Peptides Trichogin GA IV and Ampullosporin A on the Silica Nanoparticles"", 《APPL MAGN RESON》, vol. 47, pages 309 * |
| ZHENGWEI MAO等: ""Tat peptide mediated cellular uptake of SiO2 submicron particles"", 《COLLOIDS AND SURFACES B: BIOINTERFACES》, vol. 75, pages 432, XP026785546, DOI: 10.1016/j.colsurfb.2009.09.017 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021018682A1 (en) | 2021-02-04 |
| FR3099060B1 (en) | 2022-01-14 |
| FR3099060A1 (en) | 2021-01-29 |
| EP4003269A1 (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vieira et al. | Antibiofilm effect of chlorhexidine-carrier nanosystem based on iron oxide magnetic nanoparticles and chitosan | |
| Lima et al. | Antimicrobial effect of anacardic acid–loaded zein nanoparticles loaded on Streptococcus mutans biofilms | |
| Souza et al. | Green synthesis of silver nanoparticles combined to calcium glycerophosphate: antimicrobial and antibiofilm activities | |
| CN105707139B (en) | Natural anticorrosion composition | |
| US20090082429A1 (en) | Antimicrobial Compositions and Methods of Use | |
| Chen et al. | Metal‐Phenolic Network with Pd Nanoparticle Nodes Synergizes Oxidase‐Like and Photothermal Properties to Eradicate Oral Polymicrobial Biofilm‐Associated Infections | |
| US10765611B2 (en) | Water-based cosmetic composition comprising an effect pigment and a cosmetic active | |
| Jiang et al. | The pH-responsive property of antimicrobial peptide GH12 enhances its anticaries effects at acidic pH | |
| Tabassum et al. | Treatment of Staphylococcus aureus and Candida albicans polymicrobial biofilms by phloroglucinol-gold nanoparticles | |
| Karnjana et al. | The potency of herbal extracts and its green synthesized nanoparticle formulation as antibacterial agents against Streptococcus mutans associated biofilms | |
| KR101797727B1 (en) | Mild Cleansing Composition For Ladies | |
| KR102272901B1 (en) | Composition for external application to the skin containing meso-2,3-butanediol as a preservative | |
| Pulit‐Prociak et al. | Incorporation of metallic nanoparticles into cosmetic preparations and assessment of their physicochemical and utility properties | |
| KR102093827B1 (en) | Cosmetic compositions containing poly(butyl cyanoacrylate) | |
| KR102025818B1 (en) | Natural antibacterial agent and manufacturing method thereof | |
| KR101674512B1 (en) | Cosmetic composition with effect of proliferation of lactic acid bacteria and anti-bacterial activity and manufacturing method thereof | |
| Yoo et al. | Synergistic antibacterial efficacies of chlorhexidine digluconate or protamine sulfate combined with Laminaria japonica or Rosmarinus officinalis extracts against Streptococcus mutans | |
| Branco-de-Almeida et al. | Effects of 7-epiclusianone on Streptococcus mutans and caries development in rats | |
| KR20170063144A (en) | Cosmetic composition for enhancing the growth of the seed and refreshing skin comprising Duk-gu hot spring water and oilgochitosan | |
| CN114667130A (en) | Hybrid inorganic-organic complex and use thereof for maintaining the microbial balance of skin and/or cosmetic and/or dermopharmaceutical compositions | |
| Kim et al. | Chamaecyparis obtusa suppresses virulence genes in Streptococcus mutans | |
| JP4666938B2 (en) | Plant antibacterial composition | |
| Banerjee et al. | Synthesis and characterization of a lemongrass oil emulsion formulation incorporating alumina nanoparticles for activity against Streptococcus mutans isolated from dental caries | |
| Evaristo et al. | Antibacterial effect on mature biofilms of oral streptococci and antioxidant activity of 3β, 6β, 16β-trihydroxylup-20 (29)-ene from Combretum leprosum | |
| Elchaghaby et al. | Inhibitory effect of silver nanoparticles synthesized using the chamomile extract against Streptococcus mutans cariogenic pathogen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220624 |
|
| WD01 | Invention patent application deemed withdrawn after publication |